Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis

Journal of Clinical Epidemiology

Volumn 60, Issue 7, 2007, Pages

  Viala, Muriel ^a   Bhakar, Asha L ^a   de la Loge, Christine ^a   van de Velde, Helgi ^b   Esseltine, Dixie ^c   Chang, Mark ^c   Dhawan, Ravinder ^d,e   Dubois, Dominique ^d,e  

^a MAPI VALUES   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^e JOHNSON AND JOHNSON   (United States)

Author keywords

Multivariate; Partial least square regression; Patient reported outcomes; Prognosis; Survival; Univariate

Indexed keywords

BORTEZOMIB;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; CONSTIPATION; CORRELATION ANALYSIS; DATA ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; PARTIAL LEAST SQUARES REGRESSION; PATIENT REPORTED OUTCOME; PERIPHERAL SENSORY NEUROPATHY; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; SENSORY NEUROPATHY; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VOMITING;

EID: 34250028162     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2006.10.006     Document Type: Article

References (31)

1. King C.R., Haberman M., Berry D.L., Bush N., Butler L., Dow K.H., et al. Quality of life and the cancer experience: the state of knowledge. Oncol Nurs Forum 24 (1997) 27-41 In: Gunnars B, Nygren P, Glimelius B. Assessment of quality of life during chemotherapy. Acta Oncol 2001; 40(2,3):175-184
2. Gunnars B., Nygren P., and Glimelius B. Assessment of quality of life during chemotherapy. Acta Oncol 40 2, 3 (2001) 175-184
3. Bottomley A., and Flechtner H. Quality of life in oncology clinical trials: present and future changes. Expert Rev Pharmacoeconomics Outcomes Res 2 1 (2002) 84-86
4. Kramer J.A., Curran D., Piccart M., de Haes J.C., Bruning P., Klijn J., et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36 (2000) 1498-1506
5. Dancey J., Zee B., Osoba D., Whitehead M., Lu F., Kaizer L., et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res 6 2 (1997) 151-158 In: Dharma-Wardene M, Au H-J, Hanson J, et al. Baseline FACT-G score is a predictor of survival for advanced lung cancer. Qual Life Res 2004;13:1209-1216
6. Coates A., Thomson D., McLeod G.R., Hersey P., Gill P.G., Olver I.N., et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 29A 12 (1993) 1731-1734 In: Dharma-Wardene M, Au H-J, Hanson J, et al. Baseline FACT-G score is a predictor of survival for advanced lung cancer. Qual Life Res 2004;13:1209-1216
7. Van Steen K., Curran D., Kramer J., Molenberghs G., Van Vreckem A., Bottomley A., et al. Multicolinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on modem selection. Stat Med 21 (2002) 3865-3884
8. Chau I., Norman A.R., Cunningham D., Waters J.S., Oates J., and Ross P.J. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22 12 (2004) 2395-2403
9. Blazeby J.M., Brookes S.T., and Alderson D. The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut 49 (2001) 227-230
10. Roychowdhury D.F., Hayden A., and Liepa A.M. Health-related quality of life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol 21 4 (2003) 673-678
11. Eton D.T., Fairclough D.L., Cella D., Yount S.E., Bonomi P., Johnson D.H., and Eastern Cooperative Oncology Group. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group study 5592. J Clin Oncol 21 8 (2003) 1536-1543
12. Jerkeman M., Kaasa S., and Hjermstad M. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma. Med Oncol 18 1 (2001) 85-94
13. Chassany O., Sagnier P., Marquis P., Fullerton S., and Aaronson N. Patient-reported outcomes: the example of health-related quality of life-a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 36 (2002) 209-238
14. Perez-Enciso M., and Tenenhaus M. Prediction of clinical outcomes with microarray data: a Partial Least Square discriminant analysis (PLS-DA) approach. Hum Genet 112 (2003) 581-592
15. Bastien P., Esposito Vinzi V., and Tenenhaus M. PLS generalised linear regression. Computational Stat Data Anal 48 1 (2005) 17-46
16. Tenenhaus M. La regression PLS: théorie et pratique (1998), Editions Technip, France
17. Nguyen D.V., and Rocke D.M. Partial least squares proportional hazard regression for application to DNA microarray survival data. Bioinformatics 18 12 (2002) 1625-1632
18. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 26 (2003) 2609-2617
19. Dubois D., Dhawan R., van de Velde H., Esseltine D., Gupta S., Viala M., et al. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 24 6 (2006) 976-982
20. Richardson P.G., Briemberg H., Jagannath S., Barlogie B., Berenson J., Singhaal S., et al. Peripheral neuropathy following Bortezomib (VELCADE™, formerly PS-341) therapy in patients with advanced multiple myeloma: characterization and reversibility. Blood 102 (2003) Abstract 512
21. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
22. Osoba D., Zee B., Pater J., Warr D., Kaizer L., and Latreille J. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3 (1994) 353-364
23. King M.T. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5 (1996) 555-567
24. Stead M.L., Brown J.M., Velikova G., Kaasa S., Wisloff F., Child J.A., et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol 104 3 (1999) 605-611
25. Yellen S.B., Cella D.F., Webster K., Blendowski C., and Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13 2 (1997) 63-74
26. Cella D.F., Tulsky D.S., Gray G., Sarafian B., Linn E., Bonomi A., et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol 11 3 (1993) 570-579
27. Calhoun EA, Fishman DA, Roland PY, Lurain JR, Chang C, Cella D. et al. Validity and selective sensitivity of the FACT/GOG-Ntx, Proceedings of ASCO, 2000;19.
28. Eriksson L., Johansson E., Kettaneh-Wold N., and Wold S. megavariate data analysis: principles and applications (1999-2001), Umetrics AB, Sweden
29. Agresti A. Categorical data analysis. 2nd ed (2002), Wiley-Intersciences, USA
30. SIMCA-P and SIMCA-P+ 10: user guide (1992-2002), Umetrics, Sweden 10
31. Cella D., Eton D.T., Lai J.S., Peterman A.H., and Merkel D.E. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24 6 (2002) 547-561